Skip to main content

International Psoriasis Council

International Psoriasis Council
subscribe
6   What's New
Search
International Psoriasis Council
subscribe
Search

Advancing Knowledge. Improving Care.

Symposium: Optimizing the Management of Plaque Psoriasis: Insights from Experts

26TH REGIONAL CONFERENCE OF DERMATOLOGY (RCD) | KUALA LUMPUR, MALAYSIA

October 3, 2024
 | 7:30 – 8:40 UTC+8
Location: Kuala Lumpur Convention Center (KLCC) | Conference Hall 2, Level 3

Agenda

Welcome and Introduction 
Siew Eng Choon, Malaysia

Current and Emerging Systemic Treatments for Psoriasis Vulgaris
Jonathan Barker, United Kingdom

Integrating Lifestyle Modifications into Psoriasis Management
Pravit Asawanonda, Thailand

Patient Education and Empowerment in Psoriasis Care
Jonathan Barker, United Kingdom
Pravit Asawanonda, Thailand

Q&A and Closing
Siew Eng Choon, Malaysia

Program Chairs

Siew Eng Choon, MBBS, FRCP

Hospital Sultanah Aminah Johor Bahru, Clinical School Johor Bahru, Jeffrey Cheah School of Medicine and Health Services, Monash University Malaysia

Johor, Malaysia

IPC Board Member

Bio

Akimichi Morita, MD, PhD

Nagoya City University West Medical Center and Nagoya City University Graduate School of Medical Sciences

Nagoya, Japan

IPC Board Member

Bio

Program Faculty

Pravit Asawanonda, MD, MSc, DSc

Chulalongkorn University

Bangkok, Thailand

IPC Councilor

Bio

Jonathan Barker, MD

St John’s Institute of Dermatology, King’s College London

London, United Kingdom

IPC Councilor Emeritus

Bio

Novartis

What's New

When Your Patient with Psoriasis Is Diagnosed with Cancer

A patient doing well on an IL-17 inhibitor is diagnosed with cancer, and the oncologist wants the biologic stopped. It is a call most dermatologists have made without much to stand on: patients with cancer are excluded from psoriasis trials, so the entire evidence base is observational. A new IPC paper in JAAD Reviews takes a position anyway. Per the summary of product characteristics, active malignancy is not a contraindication to any biologic. IL-17 and IL-23p19 inhibitors are first-line, TNF inhibitors and deucravacitinib warrant caution, and cyclosporine is the one to avoid outright. The authors also warn that psoriasis severity is routinely underestimated once a patient is in oncology care: if they meet IPC’s criteria, they are a candidate for systemic therapy regardless of what else is on their problem list. “Too often, systemic psoriasis therapy is discontinued or never initiated in patients with cancer, even when the evidence supports safe and effective options,” says Paolo Gisondi, MD, IPC Councilor and lead author. The post includes the therapeutic options figure, designed as a reference for both specialties to work from, and a slide set for teaching and presentations.

READ NOW

Thursday, August 27, 2026

Apply Now: 2027 IPC International Fellowship Program

IPC is accepting applications for the 2027 International Fellowship Program, a 12-month opportunity for early-career dermatologists and researchers focused on psoriasis. Fellows are matched with IPC Board Members or Councilors for hands-on clinical or research experience, along with virtual mentoring, skills-development classes, and ongoing connections to IPC’s global network throughout the fellowship year. Applications are open until September 30, 2026.

APPLY NOW

Monday, August 31, 2026

IPC Generalized Pustular Psoriasis (GPP) Training Modules

Recognizing GPP in clinical practice can be a challenge, even for experienced dermatologists. IPC’s new five-part training series walks clinicians through the practical skills needed to diagnose and assess GPP with confidence: distinguishing it from plaque psoriasis and other mimicking conditions, and scoring its severity using tools such as the GPPGA and GPPASI. Each module pairs an expert-led video with a case-based exercise, and the series is built to be completed in sequence at your own pace. All five modules are free and open to everyone; watch the videos on your own or work through the assessments as you go. Score 80% or higher on each of the five assessments to earn a Certificate of Completion.

LEARN MORE

Thursday, August 13, 2026

IPC Summary Slides: Psoriasis and Metabolic Health

IPC has released a set of summary slides distilling the key findings from its recent publication on psoriasis and metabolic health, published in the Journal of the American Academy of Dermatology (JAAD). The paper outlines five priorities for improving cardiometabolic risk screening and care in patients with psoriasis. Designed for sharing, the slides give clinicians and colleagues an easy way to disseminate the findings.

LEARN MORE

Wednesday, August 5, 2026

Paradoxical Psoriasis - María Julia Cura, MD

In this Take Ten with IPC video, IPC Junior Councilor Dr. María Julia Cura discusses paradoxical psoriasis, including its definition and pathogenesis, and reviews clinical case examples, key clinical features, histopathology, predictors of disease severity, and potential treatment options.

WATCH NOW

Monday, August 3, 2026